

## Decentralised elements in Clinical Trials

3rd National Meeting on Clinical Research & Biomedical Innovation (ENICIB)

Mira Zuidgeest, PharmD PhD

University Medical Center Utrecht





Mira Zuidgeest Associate Professor University Medical Center Utrecht, NL

etpia

Imi

The research leading to these results was conducted as part of the Trials@Home consortium. This presentation only reflects the personal view of the stated authors and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.



2

### **Trials@Home project**

The aim

Provide recommendations on Decentralised Clinical Trials (DCT) approaches in Europe

Project start September 1, 2019, due to end November 30, 2025

#### The consortium



TRIALS



### What are Decentralised Clinical Trial (DCT) approaches?



"operational model in which trial activities are designed to take place at or in the vicinity of the participant's home"

"rather than at a traditional clinical site"





"This approach may make use of technologies and other innovative operational approaches to facilitate data collection"

Santa-Ana-Tellez et al. Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus. https://doi.org/10.1016/j.drudis.2023.103520

- Not a methodology
- Can be fully decentralised or hybrid
- Can be steered towards pragmatic or towards explanatory methodology
- Better recruitment and retention?
- Lower participant and site burden?
- Lower costs?
- RWE opportunities:
  - More representative study population?
  - Less interference with routine clinical practice?





### **Recommendations on decentralised elements in CTs**

From European Medicines Regulatory Network, Published Dec 14, 2022 on Eudralex Vol. 10

### **DCT Recommendation paper**

Direction of EMRN harmonisation


- 1. Introduction, scope, general considerations
- 2. Clinical trial oversight: roles & responsibilities
- 3. Informed consent process
- 4. Delivery of medicinal products & administration at home
- 5. Trial related procedures at home
- Data collection and management incl. defining & handling source data
- 7. Trial monitoring



RECOMMENDATION PAPER ON DECENTRALISED ELEMENTS IN CLINICAL TRIALS: Published Dec 14th 2022 on Eudralex Vol. 10

### National provisions overview

Member state specific provisions, where national legislation does not currently allow for alignment



# RADIAL PROOF-OF-CONCEPT STUDY

Aim: To assess the scientific and operational quality of a fully decentralised and hybrid trial approach compared to a conventional trial approach

etpia

Approved proof-ofconcept study

> Methodological objective: KPIs as main outcomes

Low intervention phase IV trial

Toujeo® used within market authorization label Population familiar with insulin use


People with DM2 treated with basal insulin with HbA1c 7-10%

<u>Acceptability:</u> safety, data quality and medical endpoints <u>Potential benefits:</u> subject retention, recruitment, diversity, cost, site & patient satisfaction


### Set-up of RADIAL proof-of-concept study

(imi) efpîa

TRIALS




### **Decentralised elements in RADIAL**





TRIALS

### **Informed Consent**



RECOMMENDATION PAPER ON DECENTRALISED ELEMENTS IN CLINICAL TRIALS: Published Dec 14th 2022 on Eudralex Vol. 10

- ICH E6: trial participants fully informed and able to ask q
- Remote informed consent may be justified, case-by-case intervention, trial complexity etc.



9 March 2023 EMA/INS/GCP/112288/2023 Good Clinical Practice Inspectors Working Group (GCP IWG)

### Guideline on computerised systems and electronic data in clinical trials

Adopted by GCP IWG for release for consultation	4 March 2021
Start of public consultation	18 June 2021
End of consultation (deadline for comments)	17 December 2021
Final version adopted by the GCP IWG	7 March 2023
Date of coming into effect	6 months after publication

This guideline replaces the 'Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials' (EMA/INS/GCP/454280/2010).

Keywords	Computerised systems, electronic data, validation, audit trail, user
	management, security, electronic clinical outcome assessment
	(eCOA), interactive response technology (IRT), case report form
	(CRF), electronic signatures, artificial intelligence (AI)

Annex 5 Additional consideration to specific systems	)
A5.1 Electronic clinical outcome assessment40	)
A5.2 Interactive response technology system45	5
A5.3 Electronic informed consent	5



### **RADIAL part B consent - Participant Experience**

**Clinpal eConsent solution with Qualified Electronic Signature** 

#### Informing (watch, read, quiz, check willingness to proceed)



For a transcript of the video, click here.

This form will give you more information about participating in the RADIAL study. The form will help you decide whether or not you would like to take part in the study. In this form you will learn:







## Consultation (video call with site)



#### Signature (opt-ins, identity, signing, download)



## **Clinical trial oversight**

Trial participant oversight and home																											
visits, in relation to RP section 2 and 5.																	T										
Q13: Is it possible for the PI to delegate																											
tasks under their responsibility to a	Yes	Yes		Yes	Yes		Yes	Yes	Vec	Yes	Yes	Y	e Ye	es   '	Yes	* Y	es	res	Yes	Yes	Yes						
qualified (for the delegated task) external	165	*		*	*		165	*	*	*	163	*	1 CS	*	Tes	Tes	*		*	•	*		*	*	*	163	165
healthcare provider?																											
Q14: Certain tasks/procedures carried																											
out at home may require supervision of		Yes		No	Yes								Yes	Yes					Ye				es	No	Voc		
the investigator (a physician). Is it	Yes	res		No	res		Yes	*	*	*	Yes	*	res	res	*	Yes	Yes	Y	es l'e	S I	Yes	* 1	es	NO	res	*	No
allowed for the physician to supervise		*		*	*								*	*									*	*	*		
remotely?																											
																						-					
Q13 Healthcare provider must	be in	direc	t denen	dency c	f the I	P																					

Q14 Should be clearly specified in the CT protocol

RECOMMENDATION PAPER ON DECENTRALISED ELEMENTS IN CLINICAL TRIALS: Published Dec 14th 2022 on Eudralex Vol. 10


- ICH E6 responsibilities stay the same
- Ensure that sponsor and investigator are able to keep oversight on trial paticipant safety and well-being



### How to maintain oversight when participants are remote?


etpia

 In decentralised/hybrid arm, the investigator has access to tools to maintain oversight – even though the participant does not physically visit the site.




### A remote site, a 24/7 clinical trial site?


- We cannot expect real-time review and follow-up on collected data and reports
- Risk-based approach
- Expectation management (for both site and participant)



## Investigator oversight in a DCT (RADIAL)

- In a conventional trial, the participant is most of the time 'remote' (<u>not at the clinical</u> <u>trial site)</u>.
- Using (novel) technology the remote participant can be brought 'closer' to the investigator







#### **RECOMMENDATION PAPER ON DECENTRALISED ELEMENTS IN CLINICAL TRIALS**

Version 01, 13 December 2022

#### **DELIVERY OF INVESTIGATIONAL MEDICINAL PRODUCTS AND ADMINISTRATION AT HOME**

Where it is intended for the IMP4 to be delivered and/or administered at the trial participant's home, a <u>risk assessment should be completed</u> to determine if such an approach is appropriate.

The <u>investigator remains responsible for the decision of treatment</u> which should be documented prior to any delivery of IMP to the trial participant's home

There are several options for delivery of the IMP to the trial participant's home, <u>depending on what is</u> <u>permitted by national requirements</u>. This can include delivery from the pharmacy of the investigator site, from a delegated pharmacy, or from a depot. The sponsor has the overall responsibility for the process and the contracts or agreements, which should reflect the principal investigator's responsibilities pursuant to ICH E6.

The sponsor should ensure that the <u>personal data</u> of the trial participants required for the delivery of the IMP is used in accordance with the <u>GDPR</u> on a need-to-know basis.

https://health.ec.europa.eu/system/files/2023-03/mp\_decentralised-elements\_clinical-trials\_rec\_en.pdf






Direct-to-Participant (DtP) shipment of IMP

### **Direct-to-Participant (DtP) shipment of IMP**

Please see relevant footnotes for responses marked with an asterisk. A footnote may be raised even though no response is given.	AT	BE	В	G CY	cz	DE BfA rM	DE PEI	DK	EE	EL	ES	FI	FR	HR	HU	IE	IS	Π	u	LT	LU	LV	мт	NL	NO	PL	PT	RO	SE	SI	SK				
The delivery of IMPs from sponsor/site, in relation to RP section 4.		-b				ŀ				-		L	ł			-			ł						1				-6	l.					
Q1: Is it possible to deliver IMPs directly to trial participants from their associated trial site?	No *	No *			Yes *	Yes *		Yes	Yes	*	Yes *	Yes	*	No *	Yes	Yes		Yes		Yes *			Yes *	Yes *	Yes	Yes	Yes *	Yes	Yes *	No *	Yes				
Q2: Is it possible to deliver IMPs directly to trial participants from the pharmacy associated with the trial site?	No *	No *			Yes *	Yes *		Yes	No *	*	Yes *	Yes *	*	No *	Yes			Yes		No *			Yes *	Yes *	Yes	Yes	Yes *	No *	Yes *	*	Yes				
Q3: Is it possible to deliver IMPs directly to trial participants from any delegated pharmacy?	No *	No *			Yes *	Yes		Yes *	No *	No *	No *	No *	Yes	No *	Yes			*		No *			No	Yes *	Yes	No *	Yes *	No *	Yes *	No *	Yes			Delegated pharmacy in	
Q4: Is it possible to deliver IMPs directly to trial participants from the IMP manufacturer with a MIA license?	No	No *			No *	No		*	No *	No *	No *	No *	No *	No *	Yes	No *		*		No *			No	No	No *	No *	Yes *	No	No	No *	No	-		country	
Q5: Is it possible to deliver IMPs directly to trial participants from the trial sponsor (sponsors intermediaries/depots)? If yes, footnote states if a licence is required for the depot to carry out this task and how to obtain this licence.	No	No *			No *	No		*	No *	No *	No *	No *	No	No *	No			*		No			No	No	No *	No *	No *	Yes *	No	*	No			Directly from sponsor	١
The shipment of IMPs from sponsor/site across boarders within the EU, in relation to RP section 4.	he depot to carry out this task and how o obtain this licence. The shipment of IMPs from sponsor/site across boarders within the EU, in relation																																		
Q6: Is it possible to deliver IMPs directly to <u>trial participants</u> from e.g. distribution/manufacturing/pharmacy licence holders located in other EU MSs if legally allowed to carry out this task in the country of origin?	No *	No *			No *	No *		Yes	No *	No *	No *	No *	No *	No *	Yes			*		No *			No	No *	No *	No *	No *	Yes	No *	No *	No			Central pharmacy abroad	
Q7: Is it possible to deliver IMPs directly to <u>investigators</u> from e.g.				PT		-																													
distribution/manufacturing/pharmacy licence holders located in other EU MSs if		Q1			ong	as sl	hippi	ing c	ond	itior	ns ar	e ke	pt u	nde	r co	ntro																			
legally allowed to carry out this task in the country of origin?		Q2	2	as I	ong	as sl	hippi	ing c	cond	itior	ns ar	e ke	pt u	nde	r co	ntro																			
RECO		Q3		_															clear															_	
		Q4																	clearl	ly ar	nd ir	n de	tail c	desc	ribe	d in t	the	СТ р	roto	col				_	
	i	Q5		-			-		-										rsion																
@HOME		Q6		-											· ·				rsion	Var	nd in	n det	tail c	lesc	ribe	lint	the	CT n	roto	col				ant n° 831458.	
	<b>Q7</b> to be											: ngs	515, 1	IVIE		iit Sl	Jour	u be	cieali	iy al	iu ii	ue		iesc	inner	иш	une i	ciþ	1010	CUI					

### **DtP IMP delivery in RADIAL**

Protocol approved in CTIS based on one general DtP IMP description



## **DtP IMP delivery in RADIAL**

**Tailored approach required** 



Be clear on what you're talking about  $\rightarrow$  4 models with difference in acceptance in different countries:

- 1. Site (pharmacy) courier participant
- 2. Central pharmacy courier participant

= Direct-to-Patient shipment


of IMP (DtP)

Telemedicine visit

etpia

- 3. Sponsor courier participant  $\rightarrow$  not in RADIAL
- 4. Local pharmacy courier participant  $\rightarrow$  not in RADIAL

Participant (V6 visit)







**@HOME** 

Moving from the theoretical to the practical: Many learnings and change accomplished through RADIAL proof-of-concept study



4 October 2022, 09:30-17:00 CET

#### EU Regulators Told To 'Normalize' Decentralized **Clinical Trials**

5-Jan 2024 NEWS



#### **Executive Summary**

EU drug regulators have received some candid responses from trial sponsors and other stakeholders on the aspects that should be urgently addressed in the next iteration of their guidance on decentralized clinical trials.

Scientists around the world speak to the importance of conducting representative research and show how when people can't make it to a study, the study needs to come to them. With new technologies and novel approaches, it is becoming increasingly evident that the way we conduct research can matter as much as the research itself.

# Thank you!

#### Further information on T@H and RADIAL:

Project website Contact us at Mira Zuidgeest www.trialsathome.com trialsathome@umcutrecht.nl m.g.p.zuidgeest@umcutrecht.nl

